POLICY STATEMENT:

I. Based upon our criteria and review of the peer reviewed literature, invasive (inserted at the time of surgery) or non-invasive (beginning at any time from the time of surgery until up to 6 months after surgery) electrical bone growth stimulation are considered medically necessary for lumbar spinal fusion surgery in individuals at high risk for pseudoarthrosis with one or more of the following risk factors for fusion failure:
   A. One or more previous failed spinal fusions; or
   B. Multi-level lumbar/lumbosacral fusion including three or more vertebrae; or
   C. Grade II or worse lumbar/lumbosacral spondylolisthesis; or
   D. History of current tobacco use; or
   E. Alcoholism; or
   F. Diabetes, renal disease, or other metabolic diseases when bone healing is likely to be compromised; or
   G. Nutritional deficiency/ malnutrition; or
   H. Osteoporosis defined as a T-score of less than -2.5 on a recent (within one year) DEXA; or
   I. Body Mass Index (BMI) greater than 30; or
   J. Severe anemia; or
   K. Glucocorticoid dependent.

II. Based upon our criteria and review of the peer reviewed literature, noninvasive electrical bone growth stimulation may be considered medically necessary as a treatment for individuals with failed lumbar spinal fusion when both of the following criteria are met:
   A. A minimum of 6 months has passed since the date of the original surgery; and
   B. Serial radiographs or appropriate imaging studies confirm there is no evidence of progression of healing/consolidation of the spinal fusion for 3 months during the latter portion of the 6 month post-fusion surgery period.

III. Based upon our criteria and review of the peer reviewed literature, invasive and noninvasive electrical stimulation are considered investigational for:
   A. Acute or chronic lumbar spondylolysis (pars interarticularis defect) with or without spondylolisthesis; or
   B. As an adjunct to cervical fusion surgery, and for failed cervical spine fusion, or failed cervical disc arthroplasty.

IV. Based upon our criteria and review of the peer reviewed literature, semi-invasive electrical bone growth stimulation is considered investigational for any indication due to lack of sufficient evidence of their effectiveness.

POLICY GUIDELINES:

I. Prior authorization is contract dependent. Please refer to your Customer (Member/Provider) Services Department for contract information.

II. Durable Medical Equipment rider/coverage is required.
III. The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

**DESCRIPTION:**

**Electrical bone growth stimulators** are used to induce the growth of bones in cases of delayed union or non-union of fractures. Two methods of electrical bone growth stimulation are available:

- **Non-invasive** stimulators use an external power supply and externally applied coils that produce an electrical current to the fracture site via pulsed electromagnetic fields (PEMFs), combined electromagnetic field (CMF) technology, or capacitive coupling to stimulate bone growth.

- **Invasive stimulators** use a current generator that is surgically implanted in an intramuscular subcutaneous space and connected to an electrode that is implanted within the bone fragments that are hoped to be fused. The power source is removed in a second surgical procedure once it has discharged.

**Failed spinal fusion** is defined as a spinal fusion that has not healed at a minimum of 6 months after the original surgery, as evidenced by serial x-rays over a course of 3 months.

**RATIONALE:**

The FDA has given premarket approval for the SpinalPak, Spinal-Stim Lite, Physio-Stim Life, OrthoPak, and SpinaLogic external stimulators and SpF implanted spinal fusion stimulators.

For individuals who are at high risk of lumbar spinal fusion failure surgery who receive invasive or noninvasive electrical bone growth stimulation, the evidence includes systematic reviews, a TEC Assessment, and randomized controlled trials (RCTs). Relevant outcomes are symptoms, change in disease status, and functional outcomes. Results from these trials have indicated that, in patients with risk factors for failed fusion, either invasive or noninvasive electrical bone stimulation increases the fusion rate. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have failed lumbar spinal fusion surgery who receive noninvasive electrical bone growth stimulation, the evidence includes a TEC Assessment and studies with patients serving as their own controls. Relevant outcomes are symptoms, change in disease status, and functional outcomes. Data have shown that noninvasive electrical stimulation improves fusion rates in this population. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who are undergoing cervical spinal fusion surgery or have failed cervical spine fusion who receive invasive or noninvasive electrical bone growth stimulation, the evidence includes 1 RCT. Relevant outcomes are symptoms, change in disease status, and functional outcomes. The only controlled trial published to date had methodologic limitations and the efficacy of electrical stimulation in the cervical spine has not been established. The evidence is insufficient to determine the effects of the technology on health outcomes.

The American Academy of Orthopedic Surgeons (AAOS) publishes information bone healing. Some broken bones do not heal even when they get the best surgical or nonsurgical treatment because of inadequate stability, the blood supply is limited or lack of good nutrition to promote healing. Some bones can be expected to heal with minimal treatment due to inherent stability and excellent blood supply (toe bones). Other bones may not heal as quickly due to a limited blood supply (femoral head and neck, small wrist bone (scaphoid). Bones with moderate blood supply (tibia) may not heal quickly because the skin and muscle over the bone was damaged and the external blood supply was impaired. In addition, certain risk factors make it more likely that a bone will fail to heal. These risk factors include tobacco or nicotine use in any form, older age, severe anemia, diabetes, hypothyroidism, infection, certain medications, and low vitamin D level.
SUBJECT: BONE GROWTH STIMULATORS; INVASIVE AND NONINVASIVE ELECTRICAL STIMULATION OF THE SPINE

POLICY NUMBER: 7.01.40
CATEGORY: Equipment/Supplies

EFFECTIVE DATE: 11/19/99
REVISED DATE: 11/02/00, 02/21/02, 01/16/03, 02/19/04, 02/24/05, 02/23/06, 12/07/06, 10/24/07, 08/28/08, 10/28/09, 04/28/11, 04/26/12, 06/28/12, 04/25/13, 04/24/14, 04/23/15, 06/22/16, 02/22/18

PAGE: 3 OF: 8

CODES:

Eligibility for reimbursement is based upon the benefits set forth in the member’s subscriber contract.

CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.

Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

CPT:

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20974</td>
<td>Electrical stimulation to aid bone healing; non-invasive (non-operative)</td>
</tr>
<tr>
<td>20975</td>
<td>invasive (operative)</td>
</tr>
</tbody>
</table>

COPYRIGHT © 2018 AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL

HCPCS:

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E0747</td>
<td>Osteogenesis stimulator, electrical, non-invasive; other than spinal applications</td>
</tr>
<tr>
<td>E0748</td>
<td>spinal applications</td>
</tr>
<tr>
<td>E0749</td>
<td>surgically implanted</td>
</tr>
<tr>
<td>E0760</td>
<td>Osteogenesis stimulator, low intensity ultrasound, non-invasive</td>
</tr>
</tbody>
</table>

ICD10:

<table>
<thead>
<tr>
<th>Code Range</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M43.22-M43.23</td>
<td>Fusion of spine, cervical region, cervicothoracic</td>
</tr>
<tr>
<td>M43.27-M43.28</td>
<td>Fusion of spine, lumbosacral, sacral and sacrococcygeal region</td>
</tr>
<tr>
<td>M51.04-M51.9</td>
<td>Thoracic, thoracolumbar, and lumbosacral intervertebral disc disorders</td>
</tr>
<tr>
<td>M53.2x7-M53.2x8</td>
<td>Spinal instabilities, lumbosacral, sacral and sacrococcygeal region</td>
</tr>
<tr>
<td>M53.3</td>
<td>Sacrococcygeal disorders, not elsewhere classified</td>
</tr>
<tr>
<td>M53.86-M53.88</td>
<td>Other specified dorsopathies, lumbosacral, sacral and sacrococcygeal region</td>
</tr>
</tbody>
</table>

REFERENCES:


*key article

**KEY WORDS:**

Bone Growth Stimulator, Osteogenic Stimulator, SAFHS, Ultrasonic Bone Growth Stimulator, US.

---

**CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS**

There is currently a National Coverage Determination (NCD) for Osteogenic Stimulators. Please refer to the following NCD website for Medicare Members: http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=65&ncdver=2&bc=BAABAAAAAAA&